Healthcare Most Active Stocks: MannKind Corporation (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Amicus Therapeutics (NASDAQ:FOLD), Geron Corporation (NASDAQ:GERN), Gilead Sciences (NASDAQ:GILD)

MannKind Corporation (NASDAQ:MNKD) VP David Thomson sold 30,000 shares of the stock on the open market in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $10.51, for a total transaction of $315,300.00. Following the transaction, the vice president now directly owns 102,286 shares in the company, valued at approximately $1,075,026. MannKind Corporation (NASDAQ:MNKD) stock performance was 9.60% in last session and finished the day at $10.96. Traded volume was 48.80million shares in the last session and the average volume of the stock remained 12.20million shares. The beta of the stock remained 1.19. MannKind Corporation (NASDAQ:MNKD) insider ownership is 0.30%.

Pfizer Inc. (NYSE:PFE) made an abortive $118 billion bid for AstraZeneca Plc, Valeant Pharmaceuticals International Inc is trying to buy Botox maker Allergan Inc for more than $50 billion, and AbbVie Inc plans to appeal to Shire Plc’s shareholders after an unsolicited $46 billion bid was rebuffed. Pfizer Inc. (NYSE:PFE) rose 0.03 percent to $29.68 Monday on volume of 20.57million shares. The intra-day range of the stock was $29.62 to $29.84. Pfizer Inc. (NYSE:PFE) has a market capitalization of $189.13billion.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) extends gains to hit a 17-month high after the biopharmaceutical company said the 18-month primary treatment period in the second phase 3 study of its Migalstat monotherapy for Fabry patients is now complete and top-line data are expected in Q3.  Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s stock on June 30, 2014 reported a increase of 10.23% to the closing price of $3.34. Its fifty two weeks range is $1.76 -$4.06. The total market capitalization recorded $214.90million. The overall volume in the last trading session was 18.55million shares. In its share capital, FOLD has 64.36million outstanding shares.

Geron Corporation (NASDAQ:GERN) on June 12 announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST). On Monday, shares of Geron Corporation (NASDAQ:GERN) advanced 8.08% to close the day at $3.21. Company return on investment (ROI) is -65.01% and its monthly performance is recorded as 54.33%. Geron Corporation (NASDAQ:GERN) quarterly revenue growth is 53.59%.

Gilead Sciences, Inc. (NASDAQ:GILD) is currently the market leader in Hepatits C treatment, and is on its way to make a fortune selling its breakthrough drug Sovaldi. The drug’s sales for 2014 may amount to anywhere between $7 billion to $12 billion, according to ISI Group. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -0.04% in last session and finished the day at $82.91. Traded volume was 10.89million shares in the last session and the average volume of the stock remained 15.01million shares. The beta of the stock remained 0.70. Gilead Sciences, Inc. (NASDAQ:GILD) insider ownership is 0.50%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone